Arguello Biosciences

Arguello Biosciences is a private, stealth-mode biotechnology company based in San Francisco, California. The company is led by President and CEO Peter DiLaura, the former CEO of Second Genome, and is backed by prominent life science investors including OrbiMed. Arguello Biosciences is focused on the discovery and development of a novel therapeutic platform, though its specific modalities, targets, and disease areas remain undisclosed to the public. As a stealth-stage entity, the company is likely engaged in early-stage pre-clinical research aimed at addressing significant unmet medical needs. The involvement of high-profile industry veterans and top-tier venture capital suggests a focus on high-impact biological innovation.